Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 923 • 2019 ACR/ARP Annual Meeting
First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?
Gulsen Ozen¹, Sofia Pedro ², Rebecca Schumacher ², Teresa Simon ³ and Kaleb Michaud ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb*, Princeton, NJ
Background/Purpose: Chronic inflammation is linked to increased risk of cardiovascular disease (CVD) in RA that may manifest as venous thromboembolism (VTE) or atherosclerotic CVD (ASCVD).…
Abstract Number: 1100 • 2019 ACR/ARP Annual Meeting
Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Christine Anastasiou¹, Jing Li ¹, Laura Trupin ², Gabriela Schmajuk ³ and Jinoos Yazdany ¹, ¹UCSF Division of Rheumatology, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) often suffer from both acute and chronic pain, and the prevalence of opioid medication…
Abstract Number: 1331 • 2019 ACR/ARP Annual Meeting
No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab
Anja Strangfeld¹, Yvette Meissner ², Martin Schaefer ³, Lisa Baganz ², Matthias Schneider ⁴, Elke Wilden ⁵, Silke Zinke ⁶ and Angela Zink ⁷, ¹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁵Rheumatologist, Cologne, Germany, ⁶Rheumatologist, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University medicine, Berlin, Germany
Background/Purpose: Spontaneous reports of nine facial paralyses and five facial pareses made by healthcare professionals from Europe have recently prompted EMA’s Pharmacovigilance Risk Assessment Committee…
Abstract Number: 1356 • 2019 ACR/ARP Annual Meeting
DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis
Jacob Greenmyer¹, John Stacy ¹, James Beal ² and Erdal Diri ¹, ¹University of North Dakota, School of Medicine Health Sciences, Minot, ND, ²University of North Dakota, School of Medicine Health Sciences, Grandforks, ND
Background/Purpose: Rheumatoid arthritis (RA) disease activity and treatment response are usually assessed by using Disease Activity Score 28-joint count (DAS28), which can be calculated using…
Abstract Number: 1381 • 2019 ACR/ARP Annual Meeting
High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis
Jun Inamo¹, Yuko Kaneko ², Jun Kikuchi ³ and Tsutomu Takeuchi ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Abatacept (ABT) is a soluble fusion protein, which links cytotoxic T-lymphocyte-associated protein 4 to the modified Fc portion of IgG1. Seropositivity and a shorter…
Abstract Number: 1417 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry
Proton Rahman ¹, Philip Baer ², Denis Choquette ³, Wojciech Olszynski ⁴, Rafat Faraawi ⁵, Louis Bessette ⁶, Milton Baker ⁷, Raman Rai ⁵, John Kelsall ⁸, Larissa Lisnevskaia ⁹, Jodie Reis ⁴, Keltie Anderson ⁴, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²Independent Rheumatology Practice, Scarborough, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Laval University, Laval, QC, Canada, ⁷Vancouver Island Health Authority, Victoria, BC, Canada, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Lakeridge Health Centre, Oshawa, ON, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose was…
Abstract Number: 1775 • 2019 ACR/ARP Annual Meeting
Cholesterol Sequestering in Macrophages Contributes to the Lipid Paradox in Chronic Arthritis
Sandra Pérez-Baos¹, Junko Arakawa ², Raquel Largo ¹, Katsunori Ikewaki ² and Gabriel Herrero-Beaumont ¹, ¹IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain, ²National Defense Medical College, Tokorozawa, Saitama, Japan
Background/Purpose: Patients with active rheumatoid arthritis (RA) have increased cardiovascular mortality, paradoxically associated with reduced circulating lipid levels. Several disease-modifying antirheumatic drugs (DMARDs), such as…
Abstract Number: 1898 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study
Signe Knudsen¹, Julia Simard ², Jakob Christensen ³, Thomas Lauersen ⁴, Bent Deleuran ⁵ and Bodil Bech ¹, ¹Department of Public Health, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ²Stanford University School of Medicine, Palo Alto, CA, ³Department of Neurology, Aarhus University Hospital & The National Center for Register-based Research, Aarhus University, Denmark, Aarhus, Denmark, ⁴The National Center for Register-based Research, Department of Economics and Business Economics, Business and Social Science, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ⁵Department of Biomedicine; Department of Rheumatology, Aarhus University, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) during pregnancy is a risk factor for several adverse pregnancy and child outcomes. Studies have found higher incidences of neurological and…
Abstract Number: 2053 • 2019 ACR/ARP Annual Meeting
Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis
Soo-Kyung Cho¹, Jun Liu ² and Seoyoung C. Kim ², ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Gout is a common inflammatory arthritis, characterized by hyperuricemia leading to crystallization of uric acid in joints. Proinflammatory cytokines have been known as an…
Abstract Number: 2250 • 2019 ACR/ARP Annual Meeting
Contribution of Personality Traits, Psychological Factors and Health Related Quality of Life on Medication Adherence in Patients with RA
Kyung Min Ko¹, Su-Jin Moon ², Jung Hee Koh ¹ and Jun-Ki Min ¹, ¹Division of Rheumatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Bucheon, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Uijeongbu, Republic of Korea
Background/Purpose: Non-adherence to long-term treatment is important in Rheumatoid arthritis (RA), as it can result in inadequate disease control and make rheumatologist to change the…
Abstract Number: 2312 • 2019 ACR/ARP Annual Meeting
Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture
Suguru Honda¹, Ryoko Sakai ², Masako Majima ¹, Naoko Konda ¹, Hideto Takada ¹, Kazuhiko Yamamoto ³, Tsutomu Takeuchi ⁴ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The risk of lymphoma is higher among patients with rheumatoid arthritis (RA) compared to general populations 1. Methotrexate (MTX), the anchor drug for RA,…
Abstract Number: 2330 • 2019 ACR/ARP Annual Meeting
Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis
Sicong Huang¹, Tianrun Cai ², Daniel Solomon ³, Zeling He ¹, Kumar Dahal ², Chuan Hong ⁴, Andrew Cagan ⁵, Seoyoung C. Kim ⁶, Jacob Joseph ⁷, Tianxi Cai ⁸ and Katherine Liao ², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁴Harvard Medical School, Boston, MA, ⁵Research Information Science and Computing, Partners Healthcare, Boston, ⁶Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁷Veterans Affairs Boston Healthcare System and Brigham and Women’s Hospital, Boston, MA, ⁸Harvard T.H. Chan School of Public Health, Boston
Background/Purpose: For patients with rheumatoid arthritis (RA), heart failure (HF) is a significant cause of morbidity and mortality. HF is further classified into 2 subtypes…
Abstract Number: 2351 • 2019 ACR/ARP Annual Meeting
Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Jeffrey Curtis¹, Yong Lin ², Karthinathan Thangavelu ³, Marina Stanislav ⁴, Gregory St John ⁵, Antonio Gómez-Centeno ⁶, Carlo Selmi ⁷, Thomas Huizinga ⁸, José Antonio Maldonado-Cocco ⁹, Marwan Bukhari ¹⁰ and Frank Buttgereit ¹¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Bridgewater, NJ, ³Sanofi Genzyme, Boston, MA, ⁴V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁷Humanitas Research Hospital, University of Milan, Milan, Italy, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Buenos Aires University School of Medicine, Buenos Aires, Argentina, ¹⁰Lancaster University Medical School, Lancaster, United Kingdom, ¹¹Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The EXTEND open-label extension study (NCT01146652) is collecting data on long-term treatment of RA with sarilumab as monotherapy and in combination with conventional synthetic…
Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
Abstract Number: 2408 • 2019 ACR/ARP Annual Meeting
A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis
Elizabeth Salt¹, Amanda Wiggins ², Kristine Lohr ² and Mary Kay Rayens ², ¹University of Kentucky, Lexington, KY, ²University of Kentucky, Lexington
Background/Purpose: Prior research suggests that medication decision-making in rheumatoid arthritis (RA) patients is affected by disease activity, satisfaction with care, trust in their health care…

« Previous Page
1
…
3
4
5
6
7
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.